


CSR02-Fab-TF Inclusion Criteria :

1. with liver cirrhosis AND at least one solid liver lesion > 2 cm.
2. Inadequate response to prior liver-directed therapy or progressive disease after prior liver-directed therapy or to one or more systemic therapies.
3. Barcelona Clinic Liver Cancer (BCLC) Intermediate Stage B or limited Advanced Stage C.
4. Child-Pugh A-B7 without clinically significant ascites
5. Subjects with prior HBV (positive HBSAg) must have HBV viral load < 500 IU/mL. Subjects with HCV infection are eligible if other eligibility criteria are met.



Proposed places for treatment with CSR02-Fab-TF

1) After standard TACE, before systemic treatment

2) After systemic treatment with liver predominate disease